Harvest Fund Management Co. Ltd Increases Holdings in Natera, Inc. (NASDAQ:NTRA)

Harvest Fund Management Co. Ltd boosted its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 90.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,774 shares of the medical research company's stock after purchasing an additional 3,697 shares during the period. Harvest Fund Management Co. Ltd's holdings in Natera were worth $987,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. acquired a new stake in shares of Natera during the 2nd quarter valued at approximately $28,000. Quarry LP lifted its position in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company's stock valued at $34,000 after acquiring an additional 190 shares during the period. GAMMA Investing LLC lifted its position in shares of Natera by 50.0% during the 2nd quarter. GAMMA Investing LLC now owns 324 shares of the medical research company's stock valued at $35,000 after acquiring an additional 108 shares during the period. Covestor Ltd lifted its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after acquiring an additional 95 shares during the period. Finally, Tobam acquired a new stake in shares of Natera during the 2nd quarter valued at approximately $74,000. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Trading Up 2.4 %

Shares of NASDAQ NTRA traded up $3.93 during trading on Tuesday, hitting $168.32. 968,661 shares of the company traded hands, compared to its average volume of 1,349,196. Natera, Inc. has a 1 year low of $53.88 and a 1 year high of $171.95. The company has a 50-day moving average price of $132.23 and a 200-day moving average price of $118.64. The firm has a market capitalization of $22.22 billion, a P/E ratio of -93.63 and a beta of 1.53. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $439.80 million during the quarter, compared to analysts' expectations of $361.43 million. During the same period in the previous year, the company earned ($0.95) EPS. The business's quarterly revenue was up 63.9% compared to the same quarter last year. On average, equities analysts predict that Natera, Inc. will post -1.66 EPS for the current year.

Insider Activity

In related news, Director Gail Boxer Marcus sold 2,212 shares of the company's stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now directly owns 19,386 shares of the company's stock, valued at approximately $3,073,262.58. This represents a 10.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Solomon Moshkevich sold 256 shares of the company's stock in a transaction on Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the sale, the insider now directly owns 111,891 shares of the company's stock, valued at approximately $13,434,752.37. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 46,503 shares of company stock valued at $6,325,804 in the last ninety days. Company insiders own 7.60% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NTRA. BTIG Research lifted their price target on shares of Natera from $125.00 to $135.00 and gave the company a "buy" rating in a research report on Friday, August 9th. TD Cowen lifted their price objective on Natera from $155.00 to $175.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Canaccord Genuity Group lifted their price objective on Natera from $150.00 to $165.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. The Goldman Sachs Group lifted their price objective on Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a research report on Wednesday, October 16th. Finally, Morgan Stanley lifted their price objective on Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $140.59.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.